ACADIA Pharmaceuticals Inc.
ACAD
Classifica tra le azioni
#4430
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Prezzo delle azioni
$20.42
Ultima sincronizzazione: 2026-10-20
Capitalizzazione di mercato
$3.52B
Variazione (1 giorno)
3.13%
Variazione (1 anno)
-3.99%
Paese
US
Scambia ACADIA Pharmaceuticals Inc. (ACAD)
Categoria
Healthcare
Ricavi di ACADIA Pharmaceuticals Inc. (ACAD)
Ricavi nel Jun 2026 TTM: $1.14B
Secondo gli ultimi rapporti finanziari di ACADIA Pharmaceuticals Inc., i ricavi attuali dell'azienda (TTM) sono pari a $1.14B. Nel 2023, l'azienda ha registrato ricavi di $726.44M un aumento rispetto a i ricavi dell'anno 2022, che erano pari a $517.24M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per ACADIA Pharmaceuticals Inc. da 2000 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $1.14B | 18.88% |
| 2024 | $957.80M | 31.85% |
| 2023 | $726.44M | 40.45% |
| 2022 | $517.24M | 6.83% |
| 2021 | $484.15M | 9.60% |
| 2020 | $441.76M | 30.28% |
| 2019 | $339.08M | 51.50% |
| 2018 | $223.81M | 79.19% |
| 2017 | $124.90M | 620.68% |
| 2016 | $17.33M | 28,311.48% |
| 2015 | $61.00K | -49.17% |
| 2014 | $120.00K | -89.52% |
| 2013 | $1.15M | -76.67% |
| 2012 | $4.91M | 137.40% |
| 2011 | $2.07M | -95.09% |
| 2010 | $42.14M | 558.46% |
| 2009 | $6.40M | 302.45% |
| 2008 | $1.59M | -78.95% |
| 2007 | $7.56M | -7.11% |
| 2006 | $8.13M | -25.77% |
| 2005 | $10.96M | 137.96% |
| 2004 | $4.60M | -37.60% |
| 2003 | $7.38M | 17.57% |
| 2002 | $6.28M | 68.97% |
| 2001 | $3.71M | -13.87% |
| 2000 | $4.31M | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | 1,008.71% |
US
|
|
| $2.23B | 95.67% |
US
|
|
| $15.74B | 1,282.73% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 428.81% |
NL
|
